147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN)A. Burnett,F. El Rassi,D. Darbari,J. Paulose,D. Lainé,D. Purkayastha,G. KatoBLOOD（2020）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
